"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
| Descriptor ID |
D017024
|
| MeSH Number(s) |
E02.186.170 E02.319.170
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 4 | 4 |
| 1996 | 0 | 6 | 6 |
| 1997 | 0 | 5 | 5 |
| 1998 | 0 | 6 | 6 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 7 | 7 |
| 2003 | 1 | 10 | 11 |
| 2004 | 2 | 3 | 5 |
| 2005 | 0 | 12 | 12 |
| 2006 | 1 | 11 | 12 |
| 2007 | 1 | 9 | 10 |
| 2008 | 2 | 9 | 11 |
| 2009 | 0 | 11 | 11 |
| 2010 | 0 | 16 | 16 |
| 2011 | 0 | 8 | 8 |
| 2012 | 1 | 12 | 13 |
| 2013 | 0 | 11 | 11 |
| 2014 | 0 | 12 | 12 |
| 2015 | 1 | 21 | 22 |
| 2016 | 1 | 12 | 13 |
| 2017 | 3 | 15 | 18 |
| 2018 | 1 | 15 | 16 |
| 2019 | 0 | 20 | 20 |
| 2020 | 0 | 8 | 8 |
| 2021 | 0 | 9 | 9 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 6 | 6 |
| 2024 | 0 | 11 | 11 |
| 2025 | 0 | 7 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
Adjuvant steroids following Kasai portoenterostomy for biliary atresia: a single-center 18-year experience comparing different steroid dose regimens. Pediatr Surg Int. 2025 Aug 19; 41(1):258.
-
National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016-2021: The impact of the KATHERINE trial. Breast Cancer Res Treat. 2025 Aug; 212(3):531-543.
-
Histologic- and Genomic-Directed Adjuvant Therapy for Ampullary Adenocarcinoma: A Hidden Genome-Derived Analysis. J Natl Compr Canc Netw. 2025 Jun; 23(6):234-240.
-
PD-L1 and Ki-67 Expression Before and After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. Int J Urol. 2025 Sep; 32(9):1195-1202.
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
-
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
-
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2025 Apr; 43(10):1229-1239.
-
Combining Biology-based and MRI Data-driven Modeling to Predict Response to Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Radiol Artif Intell. 2025 01; 7(1):e240124.
-
Long-Term Outcomes of Neoadjuvant Intraarterial Chemotherapy for Locally Invasive Lacrimal Gland Carcinoma ex Pleomorphic Adenoma. Ophthalmic Plast Reconstr Surg. 2025 Jul-Aug 01; 41(4):432-438.
-
Accuracy of pre-operative tumor size assessment compared to final pathology and frequency of adjuvant treatment in patients with FIGO 2018 stage IB2 cervical cancer. Int J Gynecol Cancer. 2024 12 02; 34(12):1861-1866.